logo
Plus   Neg
Share
Email

United Therapeutics Signs Deal With DEKA For New Remodulin Delivery System

United Therapeutics Corp. (UTHR) said it has signed an agreement with DEKA Research & Development Corp. for the development of a potential technology breakthrough in the subcutaneous delivery of Remodulin or treprostinil Injection to patients with pulmonary arterial hypertension via a pre-filled semi-disposable pump system. Financial terms of the agreement were not announced.

United Therapeutics expects to introduce the new subcutaneous Remodulin delivery system in the 2016-2018 timeframe.

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension or PAH to diminish symptoms associated with exercise.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
McDonald's Corp. has announced the return of its popular Shamrock Shake milkshake for a limited time at participating U.S. restaurants nationwide. The minty green milkshake is made with McDonald's vanilla soft serve blended with Shamrock Shake syrup and topped with whipped topping. It first debuted on the McDonald's menu in 1970 and has been a seasonal tradition for nearly 50 years. Asia-focused lender HSBC, through its blockchain-powered platform, has reduced the cost of settling foreign exchange trades by 25 percent, Reuters reported quoting a bank executive overseeing the project. Mark Williamson, chief operating officer of FX cash trading and risk management, told that the bank processes between 3,500 and 5,000 trades a day on its "FX Everywhere" system. PepsiCo, Inc. (PEP) reported fourth-quarter core EPS of $1.49 compared to $1.31, prior year. Excluding the impact of foreign exchange translation, core constant currency EPS increased 17 percent year-over-year. On average, 19 analysts polled by Thomson Reuters expected the company to report profit per...
Follow RTT